Manja Brose

2.4k total citations
25 papers, 1.3k citations indexed

About

Manja Brose is a scholar working on Pulmonary and Respiratory Medicine, Infectious Diseases and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Manja Brose has authored 25 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Pulmonary and Respiratory Medicine, 8 papers in Infectious Diseases and 8 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Manja Brose's work include Chronic Obstructive Pulmonary Disease (COPD) Research (14 papers), Mosquito-borne diseases and control (8 papers) and Viral Infections and Vectors (7 papers). Manja Brose is often cited by papers focused on Chronic Obstructive Pulmonary Disease (COPD) Research (14 papers), Mosquito-borne diseases and control (8 papers) and Viral Infections and Vectors (7 papers). Manja Brose collaborates with scholars based in United States, Switzerland and United Kingdom. Manja Brose's co-authors include Klaus F. Rabe, Leonardo M. Fabbri, Peter M.A. Calverley, Fernando J. Martínez, José Luís Izquierdo Alonso, Daniela S. Bundschuh, Udo-Michael Goehring, Dirk Bredenbröker, Emiel F.�M. Wouters and Peter Teichmann and has published in prestigious journals such as The Lancet, The Journal of Clinical Endocrinology & Metabolism and CHEST Journal.

In The Last Decade

Manja Brose

24 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Manja Brose United States	13	828	636	253	210	169	25	1.3k
Richard Gilroy United States	22	223 0.3×	214 0.3×	138 0.5×	148 0.7×	182 1.1×	65	1.9k
Richard Nieman United Kingdom	10	326 0.4×	337 0.5×	184 0.7×	21 0.1×	95 0.6×	14	708
Sami O. Simons Netherlands	17	372 0.4×	96 0.2×	81 0.3×	34 0.2×	418 2.5×	58	1.0k
Cynthia Caracta United States	21	1.4k 1.6×	1.2k 1.8×	64 0.3×	26 0.1×	154 0.9×	92	1.7k
John E. Kasik United States	16	437 0.5×	211 0.3×	93 0.4×	29 0.1×	176 1.0×	43	954
Koh Abe Japan	10	187 0.2×	121 0.2×	54 0.2×	18 0.1×	24 0.1×	24	517
Alexandre Lautrette France	10	98 0.1×	32 0.1×	140 0.6×	213 1.0×	39 0.2×	22	690
Shoji Kawachi Japan	18	227 0.3×	46 0.1×	156 0.6×	19 0.1×	152 0.9×	47	805
Rosario Casillas Spain	11	79 0.1×	94 0.1×	83 0.3×	152 0.7×	64 0.4×	27	761
Carlton K.K. Lee United States	16	166 0.2×	44 0.1×	125 0.5×	43 0.2×	84 0.5×	30	845

Countries citing papers authored by Manja Brose

Since Specialization

Citations

This map shows the geographic impact of Manja Brose's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Manja Brose with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Manja Brose more than expected).

Fields of papers citing papers by Manja Brose

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Manja Brose. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Manja Brose. The network helps show where Manja Brose may publish in the future.

Co-authorship network of co-authors of Manja Brose

This figure shows the co-authorship network connecting the top 25 collaborators of Manja Brose. A scholar is included among the top collaborators of Manja Brose based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Manja Brose. Manja Brose is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Friberg, Heather, Xavier Sáez‐Llorens, Charissa Borja-Tabora, et al.. (2024). Long term T cell response and safety of a tetravalent dengue vaccine in healthy children. npj Vaccines. 9(1). 192–192. 9 indexed citations

Low, Jenny G., Helen Oh, Yee‐Sin Leo, et al.. (2024). IgG, IgM, and Nonstructural Protein 1 Response Profiles after Receipt of Tetravalent Dengue Vaccine TAK-003 in a Phase 2 Randomized Controlled Trial. American Journal of Tropical Medicine and Hygiene. 111(1). 102–106. 4 indexed citations

Tricou, Vianney, Paul Collini, Martina Rauscher, et al.. (2023). A randomized phase 3 trial of the immunogenicity and safety of coadministration of a live-attenuated tetravalent dengue vaccine (TAK-003) and an inactivated hepatitis a (HAV) virus vaccine in a dengue non-endemic country. Vaccine. 41(7). 1398–1407. 11 indexed citations

Tricou, Vianney, Brandon Essink, John Ervin, et al.. (2023). Immunogenicity and safety of concomitant and sequential administration of yellow fever YF-17D vaccine and tetravalent dengue vaccine candidate TAK-003: A phase 3 randomized, controlled study. PLoS neglected tropical diseases. 17(3). e0011124–e0011124. 16 indexed citations

Tricou, Vianney, Xavier Sáez‐Llorens, Delia Yu, et al.. (2020). Safety and immunogenicity of a tetravalent dengue vaccine in children aged 2–17 years: a randomised, placebo-controlled, phase 2 trial. The Lancet. 395(10234). 1434–1443. 66 indexed citations

Tricou, Vianney, Jenny G. Low, Helen Oh, et al.. (2019). Safety and immunogenicity of a single dose of a tetravalent dengue vaccine with two different serotype-2 potencies in adults in Singapore: A phase 2, double-blind, randomised, controlled trial. Vaccine. 38(6). 1513–1519. 39 indexed citations

Sáez‐Llorens, Xavier, Vianney Tricou, Delia Yu, et al.. (2017). Immunogenicity and safety of one versus two doses of tetravalent dengue vaccine in healthy children aged 2–17 years in Asia and Latin America: 18-month interim data from a phase 2, randomised, placebo-controlled study. The Lancet Infectious Diseases. 18(2). 162–170. 58 indexed citations

Martínez, Fernando J., Peter M.A. Calverley, Udo-Michael Goehring, et al.. (2015). Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial. The Lancet. 385(9971). 857–866. 242 indexed citations

Calverley, Peter, Leonardo M. Fabbri, Fernando J. Martínez, et al.. (2013). Efficacy of roflumilast with concomitant cardiovascular medication in patients with COPD. European Respiratory Journal. 42(Suppl 57). 3034–3034. 1 indexed citations

10.

Hanania, Nicola A., Peter M.A. Calverley, Mark T. Dransfield, et al.. (2013). Pooled subpopulation analyses of the effects of roflumilast on exacerbations and lung function in COPD. Respiratory Medicine. 108(2). 366–375. 22 indexed citations

11.

Zheng, Jinping, Jinghua Yang, Xiangdong Zhou, et al.. (2013). Roflumilast for the Treatment of COPD in an Asian Population. CHEST Journal. 145(1). 44–52. 30 indexed citations

12.

Wedzicha, Jadwiga A., Klaus F. Rabe, Fernando J. Martínez, et al.. (2013). Efficacy of Roflumilast in the COPD Frequent Exacerbator Phenotype. CHEST Journal. 143(5). 1302–1311. 81 indexed citations

13.

Bateman, Eric D., José Roberto Jardim, Udo-Michael Goehring, Manja Brose, & Peter Calverley. (2012). Effect of roflumilast on hospitalizations in COPD patients. 40. 2109. 2 indexed citations

14.

Bateman, Eric, Klaus F. Rabe, Peter M.A. Calverley, et al.. (2011). Roflumilast with long-acting β₂-agonists for COPD: influence of exacerbation history. European Respiratory Journal. 38(3). 553–560. 87 indexed citations

15.

O’Donnell, Denis E., Dirk Bredenbröker, Manja Brose, & Katherine A. Webb. (2011). Physiological effects of roflumilast at rest and during exercise in COPD. European Respiratory Journal. 39(5). 1104–1112. 37 indexed citations

16.

McIvor, Andrew, Fernando J. Martínez, Manja Brose, & Udo-Michael Goehring. (2010). Efficacy of Roflumilast in Chronic Obstructive Pulmonary Disease Patients With or Without Inhaled Corticosteroid Pretreatment. CHEST Journal. 138(4). 464A–464A. 1 indexed citations

17.

Martínez, Fernando J., Andrew McIvor, Manja Brose, Thomas Larsson, & Udo-Michael Goehring. (2010). Benefit of Roflumilast Therapy Added to Salmeterol in Patients With Varying Chronic Obstructive Pulmonary Disease Severity. CHEST Journal. 138(4). 467A–467A. 4 indexed citations

18.

Wouters, Emiel F.�M., Peter Teichmann, Manja Brose, et al.. (2010). Effects Of Roflumilast, A Phosphodiesterase 4 Inhibitor, On Glucose Homeostasis In Patients With Treatment-Naïve Diabetes. A4471–A4471. 6 indexed citations

19.

Wouters, Emiel F.�M., Peter Teichmann, Manja Brose, Klaus F. Rabe, & Leonardo M. Fabbri. (2010). Effects Of Roflumilast, A Phosphodiesterase 4 Inhibitor, On Body Composition In Chronic Obstructive Pulmonary Disease. A4473–A4473. 13 indexed citations

20.

Fabbri, Leonardo M., Peter M.A. Calverley, José Luís Izquierdo Alonso, et al.. (2009). Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. The Lancet. 374(9691). 695–703. 431 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact